drugset / Trial / NCT00246974
Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of the study is to assess the activity of ZD1839 250 mg once daily in addition to the standard chemotherapy in patients with advanced or metastatic transitional cell carcinoma of the urothelium by estimating the time to progression.
Timeline
- Start
- 2003-05
- Primary completion
- 2007-10
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefitinib | Small molecule | 250 mg | Oral |
| Background | Cisplatin | Other / unclassified | — | Intravenous |
| Background | Gemcitabine | Small molecule | — | Intravenous |